Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
-
If you are wondering whether Evotec's current share price reflects its underlying value, it helps to start with what the market has been pricing in recently.
-
Over the last week the stock returned 24.5%, with a 29.5% return over 30 days and a 2.1% return year to date, while the 1 year return stands at an 11.8% decline and the 3 and 5 year returns show larger drawdowns of 68.2% and 83.2% respectively.
-
These moves sit against a backdrop of ongoing interest in Evotec as a listed life sciences company. News flow often centers on its role in drug discovery partnerships and broader sector sentiment. For investors, that context matters because headlines can influence risk perception even when the long term thesis has not clearly changed.
-
On Simply Wall St's valuation checks, Evotec currently has a valuation score of 4 out of 6. The sections that follow will compare what different valuation methods imply for the shares, and will then close with a way to connect those numbers to a fuller view of the company.
Find out why Evotec's -11.8% return over the last year is lagging behind its peers.
Approach 1: Evotec Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model projects a company's future cash flows and then discounts them back into today's money, aiming to estimate what the entire business might be worth right now.
For Evotec, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of €152.7 million. Analyst inputs and extrapolated estimates suggest free cash flow moving to €45.8 million by 2028, with a full set of projections running out to 2035. All of these future cash flows are converted into today's value using a discount rate. This is how the model handles the fact that money expected in later years is worth less than money received today.
Combining these discounted projections gives an estimated intrinsic value of €17.64 per share. Compared with the current share price, this implies the stock trades at a 68.0% discount, which indicates that Evotec appears undervalued on this DCF view.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Evotec is undervalued by 68.0%. Track this in your watchlist or portfolio , or discover 234 more high quality undervalued stocks .
Approach 2: Evotec Price vs Sales
For companies where earnings are not the main anchor, the P/S ratio is often a useful cross check because it relates the share price to the revenue the business is already generating, without being distorted by short term profit swings.
In general, higher growth expectations and lower perceived risk can support a higher "normal" P/S multiple, while slower growth or higher business risk usually align with a lower multiple. So context is important when comparing any single number.
Evotec currently trades on a P/S ratio of 1.27x. This sits below the Life Sciences industry average P/S of 3.91x and the peer group average of 3.60x. Simply Wall St's Fair Ratio framework estimates what an appropriate P/S might be for Evotec at 0.71x, based on factors such as its earnings profile, industry, profit margins, market capitalization and risk indicators.
That Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for the company's own growth characteristics, profitability, sector and size, instead of assuming that every Life Sciences stock should trade on the same multiple.
Comparing Evotec's actual P/S of 1.27x with the Fair Ratio of 0.71x suggests the shares trade above this model based estimate.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 99 top founder-led companies .
Upgrade Your Decision Making: Choose your Evotec Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring this to life by letting you connect your view of Evotec's business to specific forecasts for revenue, earnings and margins, then to a Fair Value that you can compare with today's share price.
On Simply Wall St's Community page, Narratives are available as an easy tool where you can see and adjust these stories. For example, one investor might lean toward the bullish view that points to a Fair Value around €10.40 with higher assumed growth and margins. Another might align with the more cautious view closer to €4.40 with slower growth and lower margins. As new information like guidance, news or earnings comes through, those Narratives and their Fair Values update so you can keep checking whether the current price sits above or below the range that matches your own assumptions.
For Evotec however we will make it really easy for you with previews of two leading Evotec Narratives:
🐂 Evotec Bull Case
Fair Value: €6.92
Implied discount vs last close: around 18.5% below this Fair Value based on the latest €5.64 share price.
Revenue growth assumption: 5.27% a year.
-
This view assumes deeper pharma partnerships, an asset-lighter licensing model and AI-enabled platforms help support recurring revenue and a higher margin mix.
-
It builds in revenue growing to €882.4m and earnings of €55.8m by 2029, with profit margins moving into positive territory.
-
It uses a 7.05% discount rate and a future P/E of 27.1x to arrive at the €6.92 Fair Value, with the current share price sitting below that level.
🐻 Evotec Bear Case
Fair Value: €4.40
Implied premium vs last close: around 28.2% above this Fair Value based on the latest €5.64 share price.
Revenue growth assumption: 2.97% a year.
-
This view assumes ongoing funding pressure in early stage biotech, cost inflation and intense competition keep a lid on revenue growth and margin progress.
-
It builds in revenue of €825.7m and earnings of €39.5m by 2029, with more modest profitability than in the bullish view.
-
It applies a 7.07% discount rate and a 24.3x future P/E to reach a €4.40 Fair Value, which is closer to the lower end of analyst targets.
If you want to see how these storylines are built in full and adjust the inputs to match your own expectations, the Community Narratives on Simply Wall St lay out every assumption side by side so you can decide which version of Evotec feels closer to your view.
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Evotec on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Do you think there's more to the story for Evotec? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EVT.DE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
